ShareValue scores for CSCI.TO: Valuation 59, Quality 25, Growth 44, Health 49.

CSCI.TO
TSX

COSCIENS Biopharma Inc.

CA$7.05(-0.28%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 18%
Valuation
59
Fair Value
Price vs Value
Quality
25
Weak
Business Strength
Growth
44
Moderate
Revenue & Earnings
Health
49
Moderate
Financial Stability
Momentum
100
Bullish
Price Trend

Company Details

About

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026